

Pfizer Limited

The Capital, 1802 / 1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel:+91 22 6693 2000 Fax:+91 22 2654 0274

ONLINE/COURIER

November 9, 2015

The Corporate Relationship Dept. BSE Limited, Phiroze Jeejeebhoy Towers, 1st Floor, Dalal Street, Fort, Mumbai- 400 001 Email: corp.relations@bseindia.com The Manager
Listing Dep.,
The National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai- 400 051.
Email: cmlist@nse.co.in

Dear Sirs,

Sub: Press Release

Please find enclosed press release for the financial results for the second quarter and six months ended September 30, 2015.

Thanking you,

Yours truly,

For PFIZER LIMITED

Praject Nair

Company Secretary

Encl: A/a

CIN: L24231MH1950PLC008311

□ contactus.india@pfizer.com

www.pfizerindia.com



Press Release For immediate dissemination

Pfizer Limited revenue up by 6% for the Quarter ended September 30, 2015

Mumbai: November 9, 2015: Pfizer Limited reported a revenue increase of 6% for the second quarter ended September 30, 2015. A very strong prior year comparative has impacted topline growth rate. Most key brands of the Company have delivered double digit growth.

EBITDA

EBITDA for Q2 is at 22.3%. Excluding a one-off VAT related accrual, EBITDA would have been higher by 1.8% points. Profit from operations for the quarter at Rs.84.6 crores grew by 30% as compared to the previous period.

Q2 Profit before Tax & Exceptional items

Profit before tax and exceptional items at Rs 101 Cr in Q2, 15-16 grew by 26% as compared to Rs 80 crore for the precious period.

Exceptional items

Exceptional items reflect proceeds from surrender of unexpired lease hold rights, partly offset by expenses in relation to Thane Plant business transfer.

For more information,

Investors: Prajeet Nair PfizerLimited

Ph.: +91-22-66932352

Email: prajeet.nair@pfizer.com

Media: Saritha Rajeev Hajare Pfizer India + 91 9619990917 saritha.hajare@pfizer.com

About Pfizer Limited:

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading



Biopharmaceutical Company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 60 years in India, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizerindia.com

Disclaimer

The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or

otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries were such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advise may be obtained and necessary due diligence, investigation etc. may be done at your end.